313653-09-7

Basic information

• Product Name: 2-Oxazolidinone, 4-methyl-3-[(4R)-4-methyl-1-oxoheptyl]-5-phenyl-, (4R,5S)-
• CAS NO: 313653-09-7
• Molecular Formula: C18H25NO3
• Molecular Weight: 303.401
• Mol File: 313653-09-7.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 4-methyl-3-[(4R)-4-methyl-1-oxoheptyl]-5-phenyl-, (4R,5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 4-methyl-3-[(4R)-4-methyl-1-oxoheptyl]-5-phenyl-, (4R,5S)-(313653-09-7)
• EPA Substance Registry System: 2-Oxazolidinone, 4-methyl-3-[(4R)-4-methyl-1-oxoheptyl]-5-phenyl-, (4R,5S)-(313653-09-7)

Safety Data

• Hazardous Substances Data: 313653-09-7(Hazardous Substances Data)

Upstream product

• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 
• 3282-30-2 pivaloyl chloride 
• 70-07-5 mephenoxalone 
• 115109-01-8 (R)-4-methylheptanoic acid 
• 7540-51-4 (S)-3,7-dimethyl-6-octen-1-ol 
• 37577-28-9 (1S,2R)-(+)-norphedrine 
• 313653-16-6 methanesulfonic Acid (S)-3,7-dimethyl-oct-6-enyl Ester 
• 208836-20-8 (R)-2,6-Dimethyl-non-2-ene 

Downstream Products

• 313653-10-0 (3S,5R)-5-methyl-3-((4R,5S)-4-methyl-2-oxo-5-phenyloxazolidine-3-carbonyl)octanoic acid tert-butyl ester 

Relevant articles and documents

Chemical development of an α2δ ligand, (3 S,5 R)-3-(Aminomethyl)-5-methyloctanoic acid

Three synthetic approaches, suitable for the large scale manufacture of the α2δ-ligand, (3S,5R)-3-(aminomethyl)-5-methyloctanoic acid 3, have been evaluated. The selected seven step manufacturing process has then been optimized and used to deliver over 20 kg of API; salient features of the synthesis include the use of 4,4,4-trimethoxybutyronitrile as an efficient four carbon amino acid equivalent. Highly selective kinetic resolution of the C3 stereocentre was accomplished via diastereoselective hydrolysis of a cyanoester intermediate using Amano Lipase PS-SD. Extensive process optimisation of the route starting from (R)-2-methylpentanol, led to significant improvements through telescoping, with less than 62 kg of solvent being needed to produce 1 kg of API.

Combinations comprising alpha-2-delta ligands

The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salths thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.

METHODS FOR USING AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA PROTEIN

This invention relates to certain ?-amino acids that bind to the alpha-2-delta ((x2S) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.